title: Treatment of gastroparesis: an update.
abstract: Gastroparesis is a chronic disorder of gastric motility that is characterized by delayed emptying of either solids or liquids from the stomach in the absence of any mechanical obstruction. Nausea, vomiting, early satiety and bloating are some of the manifestations of gastroparesis. Idiopathic, diabetes mellitus and postsurgical states account for the majority of cases. Gastroparesis is a difficult condition to treat. Prokinetic drugs like metoclopramide and erythromycin form the mainstay of therapy but are less than ideal. Some patients may benefit from endoscopic botolinium toxin injection. Gastric electrical stimulation, though promising, is not ready for prime time yet.
authors.affiliation: Department of Medicine, Mount Sinai Services at Elmhurst, Elmhurst General Hospital, Elmhurst, N.Y., USA. gumastev@yahoo.com
authors.forename: Vivek
authors.initials: V
authors.lastname: Gumaste
authors.forename: Joel
authors.initials: J
authors.lastname: Baum
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use; D004035:Diet Therapy; D018492:Dopamine Antagonists / Q000627:therapeutic use; D004599:Electric Stimulation Therapy; D004724:Endoscopy; D018589:Gastroparesis / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D018529:Nutritional Support; D011613:Psychotherapy; D011964:Receptors, Gastrointestinal Hormone / Q000819:agonists; D018013:Receptors, Neuropeptide / Q000819:agonists; D058828:Serotonin 5-HT4 Receptor Agonists; D012720:Severity of Illness Index
chemical_list: D000932:Antiemetics; D018492:Dopamine Antagonists; D011964:Receptors, Gastrointestinal Hormone; D018013:Receptors, Neuropeptide; D058828:Serotonin 5-HT4 Receptor Agonists; C050802:motilin receptor